Cellectis S.A. (EPA:ALCLS)
3.430
-0.042 (-1.21%)
Apr 28, 2026, 5:35 PM CET
Cellectis Employees
As of December 31, 2025, Cellectis had 229 total employees, including 224 full-time and 5 part-time employees. The number of employees increased by 7 or 3.15% compared to the previous year.
Employees
229
Change (1Y)
7
Growth (1Y)
3.15%
Revenue / Employee
€298,632
Profits / Employee
€253,608
Market Cap
248.99M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Transgene | 145 |
| Sensorion | 63 |
| Valneva SE | 674 |
| Genfit | 188 |
| ABIONYX Pharma | 51 |
| Innate Pharma | 174 |
| MaaT Pharma | 65 |
| Adocia | 77 |
Cellectis News
- 1 day ago - Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting - GlobeNewsWire
- 15 days ago - Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T Platform - GlobeNewsWire
- 21 days ago - Monthly information on share capital and company voting rights - GlobeNewsWire
- 5 weeks ago - Cellectis Earnings Call Transcript: Q4 2025 - Transcripts
- 5 weeks ago - Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 6 weeks ago - Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 - GlobeNewsWire
- 4 months ago - Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga
- 4 months ago - Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis - GlobeNewsWire